In 2024, around 16 percent of adults between the ages of 20 and 79 had diabetes in Turkey. Other selected countries with a high prevalence of diabetes that year included Mexico, the United States, and Portugal. Diabetes is a metabolic disease that causes high blood sugar levels. Diabetes worldwide In 2024, an estimated 11 percent of the global adult population had diabetes. In concrete numbers, there were about 589 million diabetic adults (20-79 years) worldwide in 2024, and this total is predicted to grow to approximately 852.5 million by the year 2050. Spending per patient The country that spent the most on patients with diabetes in 2024 was Switzerland. At that time, providing for a diabetic patient in Switzerland cost an average of over 12 thousand U.S. dollars. The United States stood in second place, spending about 10,500 U.S. dollars per patient. In the same year, the ten countries by lowest average spending per person with diabetes were all African and Asian countries. Bangladesh had the lowest annual diabetes-related health expenditures per person, with just 74 U.S. dollars.

In 2024, more than ** percent of the population aged 20 to 79 years in Pakistan had diabetes. In comparison, Timor-Leste had the lowest prevalence of diabetic people aged 20 to 79 across the Asia-Pacific region that year, approximately *** percent.

By 2050, the Western Pacific region is forecast to have the highest number of diabetic people worldwide, with some 254 million people aged between 20 and 79 years. Diabetes in the future Between 2024 and 2050, the number of diabetics is set to increase in all regions worldwide. Diabetes rates are expected to increase the most in Africa, by roughly 142 percent. Throughout this period, Europe is projected to show the smallest increase, with about 10 percent. In 2050, the countries with the highest number of diabetics are expected to be China with some 168 million and India with about 157 million. At that time, about 43 million people are projected to have diabetes in the United States. Children with type 1 diabetes In 2024, the country with the highest estimated number of children and adolescents (between the ages of 0 and 19) with type 1 diabetes was India, which had some 301 thousand diabetic children and adolescents. The United States came second with around 197 thousand. Considering the U.S. population is significantly smaller than that of India, there is a higher percentage of children with type 1 diabetes in the United States.

Portugal had the highest prevalence of diabetes in Europe among their adult population with **** percent living with diabetes, as of 2024, Croatia followed with the second-highest share at **** percent. Conversely, Ireland was the country with the lowest prevalence of diabetes in Europe at *** percent. Diabetes-related deaths The highest number of diabetes-related deaths in Europe, at almost ******, was recorded in Germany in 2024. Italy and France followed, with roughly *******and ****** deaths, respectively. Diabetes risk factors in Europe One of the major contributing factors to type 2 diabetes is being overweight or obese. As of 2022, Greece had the highest share of overweight population across Europe, with *****percent. The lack of sports and exercise is also another risk factor. As of 2022, Portugal was the European country with the highest share of people never exercising or engaging in sports, with ** percent.

The average for 2021 based on 27 countries was 6.24 percent. The highest value was in Spain: 10.3 percent and the lowest value was in Ireland: 3 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Global Diabetes Medicine Sales by Country, 2023 Discover more data with ReportLinker!

In 2024, Pakistan had the highest prevalence of diabetes worldwide, with around ** percent of the population suffering from the disease. Diabetes mellitus, or simply, diabetes, refers to a group of metabolic disorders that cause high blood sugar levels. Diabetes can be prevented and treated though exercise, maintaining normal body weight, and healthy eating, but is usually managed with insulin injections. Costs As of 2024, there were almost *** million people worldwide who had diabetes. With such a huge number of people suffering from this disease, it is no surprise that spending on diabetes can be very high. It is estimated that the United States alone spent around ***** billion U.S. dollars on diabetes health expenditure in 2024. The countries with the highest spending per patient with diabetes include Switzerland, the United States, and Norway. Death Diabetes is among the leading ten causes of death worldwide, accounting for around **** million deaths in 2021. Complications resulting from diabetes include chronic kidney disease, stroke, and cardiovascular disease. The risk of early death is at least doubled among those with diabetes. The Western Pacific reports the highest number of deaths from diabetes, followed by North America and the Caribbean.

Global Diabetes Mellitus Mortality by Country, 2023 Discover more data with ReportLinker!

Global Diabetes Prevalence by Country, 2021 Discover more data with ReportLinker!

Diabetes prevalence is projected to increase across all world regions by 2050, with the Middle East and North Africa expected to face the highest rates at 21 percent. This alarming trend highlights the growing global health challenge posed by diabetes, which already affects hundreds of millions of people worldwide and strains healthcare systems. Global impact and economic burden The number of diabetics globally is set to rise from nearly 589 million in 2024 to around 853 million by 2050. This surge in cases is accompanied by a significant economic burden, with global expenditures for diabetes treatment expected to grow from about 1.02 trillion U.S. dollars in 2024 to approximately 1.04 trillion U.S. dollars by 2050. The United States alone is projected to spend around 404.5 billion U.S. dollars on diabetes-related healthcare in 2024, underscoring the massive financial implications of this chronic condition. Regional disparities and future outlook While the Middle East and North Africa region is projected to have the highest diabetes prevalence by 2050, other regions will also see substantial increases. Africa is expected to experience a 142 percent rise in diabetic cases from 2024 to 2050, despite having the lowest prevalence among world regions. China is anticipated to remain the country with the highest number of diabetics, reaching approximately 168 million cases by 2050. Notably, Pakistan is forecast to surpass the United States in terms of diabetic population by mid-century, reflecting shifting global health dynamics and the need for targeted interventions in developing nations.

BackgroundThe incidence of Type 1 Diabetes (T1D) in children varies dramatically between countries. Part of the explanation must be sought in environmental factors. Increasingly, public databases provide information on country-to-country environmental differences.MethodsInformation on the incidence of T1D and country characteristics were searched for in the 194 World Health Organization (WHO) member countries. T1D incidence was extracted from a systematic literature review of all papers published between 1975 and 2014, including the 2013 update from the International Diabetes Federation. The information on country characteristics was searched in public databases. We considered all indicators with a plausible relation with T1D and those previously reported as correlated with T1D, and for which there was less than 5% missing values. This yielded 77 indicators. Four domains were explored: Climate and environment, Demography, Economy, and Health Conditions. Bonferroni correction to correct false discovery rate (FDR) was used in bivariate analyses. Stepwise multiple regressions, served to identify independent predictors of the geographical variation of T1D.FindingsT1D incidence was estimated for 80 WHO countries. Forty-one significant correlations between T1D and the selected indicators were found. Stepwise Multiple Linear Regressions performed in the four explored domains indicated that the percentages of variance explained by the indicators were respectively 35% for Climate and environment, 33% for Demography, 45% for Economy, and 46% for Health conditions, and 51% in the Final model, where all variables selected by domain were considered. Significant environmental predictors of the country-to-country variation of T1D incidence included UV radiation, number of mobile cellular subscriptions in the country, health expenditure per capita, hepatitis B immunization and mean body mass index (BMI).ConclusionsThe increasing availability of public databases providing information in all global environmental domains should allow new analyses to identify further geographical, behavioral, social and economic factors, or indicators that point to latent causal factors of T1D.

The graph shows the changes in the impact factor of ^ and its corresponding percentile for the sake of comparison with the entire literature. Impact Factor is the most common scientometric index, which is defined by the number of citations of papers in two preceding years divided by the number of papers published in those years.

The average for 2021 based on 47 countries was 5.59 percent. The highest value was in Mauritius: 22.6 percent and the lowest value was in Benin: 1.1 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

This statistic shows the top 10 countries based on number of new cases of type 1 diabetes per 100,000 children aged 0 to 14 years, in 2021. Finland had the highest rate with 52.2 new cases per 100,000 children per year.

Type-1 Diabetes Treatment Market Outlook

The global Type-1 Diabetes Treatment market size is projected to grow significantly from USD 7.2 billion in 2023 to an estimated USD 12.6 billion by 2032, at a compound annual growth rate (CAGR) of 6.5%. The market growth is primarily driven by the rising prevalence of Type-1 diabetes worldwide, coupled with advancements in medical technology and treatment methods. Additionally, increasing awareness and early diagnosis of the disease have been pivotal in expanding the market's reach.

One of the major growth factors for the Type-1 Diabetes Treatment market is the continuous development and approval of innovative insulin delivery systems. Technologies such as insulin pumps, continuous glucose monitors, and artificial pancreas systems are revolutionizing diabetes care by offering more precise and convenient methods for managing blood sugar levels. These advancements not only improve the quality of life for patients but also reduce long-term complications associated with poor blood glucose control, thereby driving market expansion.

Another significant growth driver is the increasing investment in research and development by pharmaceutical companies. Efforts to discover new treatment modalities, including non-insulin therapies and regenerative medicine approaches like pancreas and islet cell transplantation, are creating new opportunities within the market. Additionally, collaborations between academic institutions and biotech firms are accelerating the pace of innovation, bringing novel therapies closer to commercial availability.

The market is also supported by favorable government initiatives and policies aimed at improving diabetes care. Many countries are implementing national diabetes programs that include guidelines for early diagnosis, comprehensive care plans, and subsidies for treatment costs. These programs are essential in increasing access to effective treatments, particularly in low and middle-income countries where the burden of diabetes is rising rapidly.

In recent years, Diabetes Stem Cell Therapy has emerged as a promising area of research in the treatment of Type-1 diabetes. This innovative approach involves the use of stem cells to regenerate insulin-producing beta cells in the pancreas, potentially offering a more permanent solution to insulin dependency. Researchers are exploring various sources of stem cells, including embryonic stem cells and induced pluripotent stem cells, to develop effective therapies. The ultimate goal is to restore the body's ability to produce insulin naturally, thereby reducing or eliminating the need for external insulin administration. While still in the experimental stages, early clinical trials have shown encouraging results, paving the way for future advancements in this field.

Regionally, North America dominates the Type-1 Diabetes Treatment market, accounting for the largest share due to high healthcare expenditure, advanced healthcare infrastructure, and significant investment in diabetes research. Europe follows closely, with a strong focus on improving healthcare outcomes and increasing awareness about diabetes management. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by the rising prevalence of diabetes, improving healthcare infrastructure, and increasing government initiatives to enhance diabetes care. Latin America and the Middle East & Africa also show promising growth potential, although these markets are currently smaller in size compared to North America and Europe.

Insulin Therapy Analysis

Insulin therapy remains the cornerstone of Type-1 diabetes treatment, accounting for a significant share of the market. The evolution of insulin formulations, including rapid-acting, long-acting, and intermediate-acting insulins, has provided patients with more options to tailor their treatment plans to their specific needs. Innovations such as biosimilar insulins have also made treatments more accessible by offering cost-effective alternatives to branded products. Continuous advancements in insulin delivery systems, such as smart insulin pens and pumps, are further enhancing the efficacy and convenience of insulin therapy.

Recent developments in insulin therapy include the advent of ultra-rapid-acting insulins, which aim to better mimic the body's natural insulin response to meals. These insulins provide faster onset and shorter durat

Global Potential Years of Life Lost from Diabetes Mellitus by Country, 2023 Discover more data with ReportLinker!

The average for 2021 based on 24 countries was 10.54 percent. The highest value was in Mexico: 16.9 percent and the lowest value was in Aruba: 4.3 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

The objective of this study was to compare the effect of diabetes and pathologies potentially related to diabetes on the risk of infection and death from COVID-19 among people from Highly-Developed-Country (HDC), including Italians, and immigrants from the High-Migratory-Pressure-Countries (HMPC). Among the population with diabetes, whose prevalence is known to be higher among immigrants, we compared the effect of body mass index among HDC and HMPC populations. A population-based cohort study was conducted, using population registries and routinely collected surveillance data. The population was stratified into HDC and HMPC, according to the place of birth; moreover, a focus was set on the South Asiatic population. Analyses restricted to the population with type-2 diabetes were performed. We reported incidence (IRR) and mortality rate ratios (MRR) and hazard ratios (HR) with 95% confidence interval (CI) to estimate the effect of diabetes on SARS-CoV-2 infection and COVID-19 mortality. Overall, IRR of infection and MRR from COVID-19 comparing HMPC with HDC group were 0.84 (95% CI 0.82–0.87) and 0.67 (95% CI 0.46–0.99), respectively. The effect of diabetes on the risk of infection and death from COVID-19 was slightly higher in the HMPC population than in the HDC population (HRs for infection: 1.37 95% CI 1.22–1.53 vs. 1.20 95% CI 1.14–1.25; HRs for mortality: 3.96 95% CI 1.82–8.60 vs. 1.71 95% CI 1.50–1.95, respectively). No substantial difference in the strength of the association was observed between obesity or other comorbidities and SARS-CoV-2 infection. Similarly for COVID-19 mortality, HRs for obesity (HRs: 18.92 95% CI 4.48–79.87 vs. 3.91 95% CI 2.69–5.69) were larger in HMPC than in the HDC population, but differences could be due to chance. Among the population with diabetes, the HMPC group showed similar incidence (IRR: 0.99 95% CI: 0.88–1.12) and mortality (MRR: 0.89 95% CI: 0.49–1.61) to that of HDC individuals. The effect of obesity on incidence was similar in both HDC and HMPC populations (HRs: 1.73 95% CI 1.41–2.11 among HDC vs. 1.41 95% CI 0.63–3.17 among HMPC), although the estimates were very imprecise. Despite a higher prevalence of diabetes and a stronger effect of diabetes on COVID-19 mortality in HMPC than in the HDC population, our cohort did not show an overall excess risk of COVID-19 mortality in immigrants.